Objective To investigate the clinical efficacy of Ginkgo biloba diterpenoid lactone glucosamine combined with edaravone dextrogenol in the treatment of acute ischemic stroke in patients as well as its effect on neurological function and levels of inflammatory factors.Methods A retrospective case-control study was conducted on the clinical data of 86 patients with acute ischemic stroke who received treatment at Jiulong Hospital ofJiaozhou from December 2021 to October 2023.The patients were divided into two groups based on their treatment regimens,with 43 patients in each group.Both groups received standardized conventional treatment.The control group received additional treatment with edaravone dextrogenol,while the observation group was given Ginkgo biloba diterpenoid lactone glucosamine in addition to the treatments provided to the control group.All patients were treated for 14 days.The clinical efficacy of both groups was assessed.The National Institutes of Health Stroke Scale score,serum C-reactive protein level,and lipoprotein-associated phospholipase A2 level were compared before and after treatment.The incidence of adverse reactions during the whole treatment period was compared between the two groups.Results After 14 days of treatment,the National Institutes of Health Stroke Scale score in the observation group was(7.09±2.15)points,which was significantly lower than that of the control group[(8.23±2.97)points,t=-2.04,P=0.045].The clinical efficacy of the observation group was significantly superior to that of the control group(Z=1.62,P=0.011).The serum levels of C-reactive protein and lipoprotein-associated phospholipase A2 in the observation group were(14.53±5.05)mg/L and(169.95±17.62)μg/L,respectively,which were significantly lower than those in the control group[(16.88±5.46)mg/L,(178.53±20.34)μg/L,t=-2.07,-2.09,P=0.047,0.040].There was no significant difference in the incidence of adverse reactions between the two groups(x2=0.09,P=0.763).Conclusion The combination of Ginkgo biloba diterpenoid lactone glucosamine and edaravone dextrogenol for the treatment of acute ischemic stroke in patients is effective and reliable.This combined therapy exhibits a good neuroprotective effect,helps improve neurological function,reduces inflammatory responses,and does not increase the incidence of adverse reactions.
StrokeHypoxia-ischemia,brainDrug therapy,combinationNervous system diseasesNational institute of neurological disorders and strokeC-reactive proteinPhospholipases A2Ginkgo biloba diterpenoid lactoneEdaravonedextrogenol
维普
万方数据
